SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on July 10, 2012, covering events occurring on July 5, 2012. The registrant is incorporated in Colorado and maintains its principal executive offices in Castle Rock, CO. The filing addresses regulatory compliance status with The NASDAQ Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a notification of a regulatory event.
Material Changes
The primary material event reported is the Company's regained compliance with NASDAQ Listing Rule 5550(a)(2), which establishes minimum closing bid price requirements for listed companies. This compliance was confirmed by NASDAQ correspondence received on July 5, 2012.
Outlook, Risks, and Management Commentary
On July 10, 2012, the Company issued a press release (attached as Exhibit 99.1) confirming it had regained compliance with all NASDAQ Capital Market continued listing standards. No specific forward-looking guidance, risk factors, or unusual items were detailed within the text of this specific 8-K filing.
Investor Verification Checklist
- Verify the current stock price to ensure continued compliance with NASDAQ minimum bid price requirements.
- Review the attached press release (Exhibit 99.1) for any additional details regarding the compliance timeline.
- Check subsequent filings for any renewed delisting notices or compliance warnings.
- Confirm the Company's operational status and financial health through its most recent 10-K or 10-Q, as this 8-K contains no financial data.